Bioconjugate companies develop technologies that chemically link biological molecules to drugs, imaging agents, polymers or other functional components. These approaches are used to improve targeting, stability, delivery and detection across therapeutics, diagnostics and life science research.
This category includes companies working on:
Browse 33 UK bioconjugate companies below.
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate…
CDMO and CRO for complex biologics and bioconjugate development
Abzena is an integrated CDMO and CRO specialising in complex biologics and bioconjugates, with cGMP facilities across the United States and a research presence in Cambridge, UK.…
Contract antibody production, purification, and conjugation services
The Antibody Company is a contract research organisation specialising in the production, purification, and conjugation of monoclonal and polyclonal antibodies. The company serves…
AI-designed aptamer therapeutics for undruggable targets
PentaBind is a TechBio company using generative AI to design aptamers with drug-like properties for targets that are inaccessible to conventional modalities. Its platform combines…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal…
Contract immunoassay development and bioconjugation services
Fleet Bioprocessing is a Hampshire-based contract development and manufacturing organisation specialising in immunoassay development and bioconjugation. Founded in 2000 by former…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline…
Constrained bicyclic peptide conjugates for targeted cancer therapy
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on short synthetic peptides constrained by a small molecule…
Contract chemistry and manufacturing solutions for pharmaceutical and biotech research
Chemveda Life Sciences is a contract research and development organisation providing chemistry solutions to the pharmaceutical, biotechnology and agrochemical industries. The…
Bispecific antibody-drug conjugates for hard-to-treat solid tumours
Valink Therapeutics is a biotechnology company developing next-generation bispecific antibody-drug conjugates and multispecific antibody therapeutics for oncology. Its proprietary…
End-to-end lateral flow immunoassay development and manufacturing
Global Access Diagnostics (GADx) is a contract developer and manufacturer of rapid lateral flow immunoassay tests for human, veterinary, and agricultural applications. Operating…